AAV Vectors in Gene Therapy Pipeline Landscape Report 2024: Comprehensive Insights about 70+ Companies and 235+ Pipeline Drugs
April 19, 2024 07:31 ET
|
Research and Markets
Dublin, April 19, 2024 (GLOBE NEWSWIRE) -- The "AAV vectors in gene therapy - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This "AAV vectors in gene...
Global Cell and Gene Therapy Markets Report 2024-2028 Featuring Main Players - Mallinckrodt, Vericel, Gilead Sciences, Pharmicell, and Bristol-Myers Squibb
April 03, 2024 03:10 ET
|
Research and Markets
Dublin, April 03, 2024 (GLOBE NEWSWIRE) -- The "Global Cell and Gene Therapy Market" report has been added to ResearchAndMarkets.com's offering. The Global Cell and Gene Therapy Market is...
The adeno associated viral vector / AAV vector market is anticipated to grow at a CAGR of more than 10% by 2035, claims Roots Analysis
October 27, 2022 12:38 ET
|
Roots Analysis
London, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Adeno Associated Viral Vector / AAV Vector Market, 2022-2035” report to its list of offerings. Owing to...
Asklepios BioPharmaceutical, Inc. Announces Former Portfolio Company’s Preclinical Asset for Duchenne Muscular Dystrophy Has Advanced into the Clinic
April 25, 2018 08:05 ET
|
Asklepios BioPharmaceutical, Inc.
Pfizer, Inc. Dosed First Patient in its Mini-Dystrophin Gene Therapy Phase 1b Trial Another AskBio Platform Product to be Acquired by Big Pharma Novartis CHAPEL HILL, N.C., April 25, 2018 (GLOBE...